Aydan Kilicarslan

Aydan Kilicarslan

Auto-generated profile, based on publicly available information

Aydan Kilicarslan

Department of Pathology, Ankara Yildirim Beyazit University, Ankara, Turkey

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2021 in Drug Design, Development and Therapy
Verified
Journal Article
Open access
PDF file
AKAyşegül Küçük
Ayşegül Küçük
YPYücel Polat
Yücel Polat
AKAydan Kılıçarslan
Aydan Kılıçarslan
NSNuran Süngü
Nuran Süngü
HKHakan Kartal
Hakan Kartal
Mustafa ArslanMustafa Arslan
Mustafa Arslan
Aim: The aim of this study was to evaluate the effects of irisin in a murine model of hind limb ischemia reperfusion (I/R). Methods: The mice were divided into four groups (n = 6 in each group): control, irisin, ischemia reperfusion (I/R), and irisin-ischemia reperfusion (I–I/R). Irisin (0.5 μg.g− 1, intraperitoneally [i.p.]) was administered 30 min before the I/R procedure. After 2 h of ischemia and 2.5 h of reperfusion, blood and tissue samples were taken for biochemical and histopathological analysis. The results were analyzed by Kruskal–Wallis and Mann–Whitney U-tests. Results: There was a statistically significant difference in the total antioxidant status (TAS) and total oxidant status (TOS) levels in all the groups. The TAS level in the I/R group was significantly lower than that in the control, irisin, and I–I/R groups, whereas the TOS level was significantly higher in the I/R group as compared with that in the other groups. Caspase-3 activity and caspase-8 activity, indicators of inflammation, were significantly higher in the I/R and I–I/R groups as compared with those in the control and irisin groups. Conclusion: Irisin may have protective effects in skeletal muscle ischemia reperfusion injury.

10 July 2024 in Endocrine
Verified
Journal Article
Open access
PDF file
FKFatma Dilek Dellal Kahramanca
Fatma Dilek Dellal Kahramanca
MSMuhammet Sacikara
Muhammet Sacikara
AKAydan Kilicarslan
Aydan Kilicarslan
BOBerna Ogmen
Berna Ogmen
CACevdet Aydin
Cevdet Aydin
BCBekir Cakir
Bekir Cakir
Purpose: To determine whether early repeat fine needle aspiration biopsy (FNA) has an effect on adequate or atypia of undetermined significance (AUS) cytology rates in thyroid nodules with inadequate or AUS result in the first FNA. Methods: Nodules of patients who underwent repeat biopsy due to insufficient or AUS cytology between 2019–2022 were included. Data of the patients and ultrasonographic, cytological and histopathological results of the nodules were recorded. Additionally, the time between the two biopsies was noted. The first was called “initial” and the second was called “rebiopsy”. Five different paired groups were formed according to the time between two consecutive biopsies; before and after 1 month, 45 days, 2 months, 3 months, and 6 months. The groups were compared in terms of adequate and AUS cytological results. Results: We evaluated 1129 patients with 2187 nodules undergoing FNAB. After excluding nodules with one FNA result and/or missing data, 966 nodules of 628 patients who underwent FNA at least twice were included. Initial cytology was nondiagnostic (ND) in 665 (30.4%) and AUS in 301 (13.8%) nodules. The mean age of the patients was 52.0 ± 11.9 years, and the female sex ratio was 78.8% (n = 495). There were no differences in adequate or AUS rebiopsy results according to the different time interval groups (p > 0.05 for all). AUS result was statistically insignificantly more frequent in nodules with initially AUS nodules when rebiopsy was performed before 1 month in comparison to after 1 month (53.8%, 27.1%; p = 0.054). Accuracy of rebiopsy was also similar in the time intervals groups (p > 0.05 for all). Conclusion: In patients with inadequate or AUS initial biopsy, the rate of adequate or AUS cytology results at rebiopsy did not vary with the timing of repeat biopsy indicating that there may be no need to wait 1 month for a repeat biopsy. In patients with suspicious nodules, biopsy might be repeated before 1 month.

18 February 2025 in TURKISH JOURNAL OF MEDICAL SCIENCES
Verified
Journal Article
Open access
PDF file
AKAydan Kiliçarslan
Aydan Kiliçarslan
GÇGülnaz Kurt Çevi̇k
Gülnaz Kurt Çevi̇k
MDMEHMET DOĞAN
MEHMET DOĞAN
AAAyşegül Aksoy Altinboğa
Ayşegül Aksoy Altinboğa
FCFunda Ceran
Funda Ceran
GEGülşah Efeci̇k
Gülşah Efeci̇k
Background/aimHodgkin Lymphoma (HL) is highly treatable, but new chemotherapy agents are needed for patients with progression or recurrence. CD47 regulates anti-phagocytic activity by signaling through the SIRPα (signal regulatory protein alpha) pathway on macrophages. This study aims to assess the expression of CD47 in HL cases and explore its relationship with Epstein-Barr Virus (EBV) status and the International Prognostic Index (IPI).Materials and Methods120 patients diagnosed with Classical HL, characterized by the presence of Hodgkin and Reed-Sternberg (HRS) cells, for whom IPI scores were available. Demographic data and EBV status were retrieved from hospital records. CD47 immunohistochemical expression in HRS cells was evaluated based on its prevalence and intensity. The product of these two values was used to calculate the CD47 expression score.ResultsOf the 120 cases, 76 (63.33%) were male and 44 (36.66%) were female, with an average age of 38.77 years. EBV ISH test results were available for 93 cases, of which 48 (51.61%) were positive. CD47 expression was 67% on average, and cases were categorized based on CD47 expression scores of ≤6 and >6 and IPI scores of ≤2 and >2. No significant relationship was found between CD47 expression score and age(p:0,990), gender(p: 0.086), EBV status(p: 0.374), or IPI score(p: 0.805). However, higher IPI scores were significantly associated with increased EBV positivity (p: 0.041).ConclusionCD47 was widely expressed, but no significant relationship with clinical parameters was observed. Further studies are required to validate its role as a biomarker.

15 July 2024 in Archives of Endocrinology and Metabolism
Verified
Journal Article
Open access
PDF file
EKEkin Yiğit Köroğlu
Ekin Yiğit Köroğlu
KTKübra Turan
Kübra Turan
FAFeride Pınar Altay
Feride Pınar Altay
FKFatma Dilek Dellal Kahramanca
Fatma Dilek Dellal Kahramanca
AKAydan Kiliçarslan
Aydan Kiliçarslan
BÇBekir Çakir
Bekir Çakir
SUMMARY Malignant mesenchymal thyroid tumors are one of the rarest types of thyroid cancer. Clinically, these tumors present as a rapidly growing thyroid mass. Due to their rarity and nonspecific findings, they are not the first conditions that come to mind during differential diagnosis. We report herein the case of an 87-year-old woman presenting with a rapidly growing thyroid mass in whom the differential diagnosis of anaplastic cancer was challenging. Following work up, the patient was diagnosed with primary fibrosarcoma [...] SUMMARY Malignant mesenchymal thyroid tumors are one of the rarest types of thyroid cancer. Clinically, these tumors present as a rapidly growing thyroid mass. Due to their rarity and nonspecific findings, they are not the first conditions that come to mind during differential diagnosis. We report herein the case of an 87-year-old woman presenting with a rapidly growing thyroid mass in whom the differential diagnosis of anaplastic cancer was challenging. Following work up, the patient was diagnosed with primary fibrosarcoma


24 August 2020 in Archives of Endocrinology and Metabolism
Verified
Journal Article
Open access
PDF file
NSNeslihan Cuhaci Seyrek
Neslihan Cuhaci Seyrek
HBHusniye Baser
Husniye Baser
OTOya Topaloglu
Oya Topaloglu
DODidem Ozdemir
Didem Ozdemir
AKAydan Kilicarslan
Aydan Kilicarslan
BCBekir Cakir
Bekir Cakir
We aimed to evaluate the patients diagnosed with papillary thyroid carcinoma (PTC) and papillary thyroid microcarcinoma (PTMC) in terms of clinical, ultrasonographical (US) and histopathological features and their relationships with tumor size. We retrospectively evaluated 881 patients who underwent thyroid surgery in our clinic and diagnosed with PTC histopathologically were enrolled the study. Demographic characteristics, US findings and histopathological features were evaluated. In total, 1264 nodules were identified in the 881 patients. The incidentality rates were higher in the PTMC group and also in the ≤ 5 mm group. In total multifocality rate was 32.9%, and was significantly higher in PTMC group than the PTC group. PTC and > 5 mm PTMC groups compared to PTMC and ≤ 5 mm groups respectively, were more aggresive histopathological features. Since the incidentality rates were found significantly more common in our patients with PTMC and those with ≤ 5 mm, ultrasonographic features of the nodules should be evaluated carefully and for cases which are suspicious with US, US-guided fine needle aspiration biopsy (FNAB) should be considered in order to make the correct treatment strategy. Also our study revealed that PTC and > 5 mm PTMC groups compared to PTMC and ≤ 5 mm groups respectively, have more aggresive histopathological features.